Sivextro

Selected form

Tedizolid Phosphate

Treatment option: Infection

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sivextro

Quick Facts

Property	Description
Active Ingredient	Tedizolid Phosphate
Pharmacological Class	Oxazolidinone-Class Antibacterial
Form	Tablet (Oral), Powder for Infusion (Intravenous)
General Purpose	To combat serious bacterial infections
Origin	Synthetic, Second-Generation

SIVEXTRO: Classification and General Therapeutic Purpose

SIVEXTRO is a synthetic, prescription-only systemic antibacterial agent classified within the Oxazolidinone pharmacological group. It is a second-generation oxazolidinone-class antibiotic, which distinguishes it from earlier agents in this category. The active component is Tedizolid Phosphate, which functions as a prodrug, a preparatory form that is quickly converted to the active compound, Tedizolid.

This medication’s primary function is to exert bacteriostatic activity against targeted Gram-positive pathogens. Tedizolid provides a potent, targeted mechanism of action against certain bacteria. This means the drug is designed to effectively inhibit the growth and reproduction of the specific bacteria causing an infection, a strategy typically reserved for managing specific, serious infectious conditions.

Composition, Form, and the Prodrug Principle

Tedizolid Phosphate is formulated as a prodrug because the body rapidly converts it into the active substance, Tedizolid, through the action of endogenous plasma phosphatases. Once activated, Tedizolid achieves its core effect by binding to the bacterial 50S ribosomal subunit, which is the site of protein synthesis, effectively halting the bacteria’s ability to build necessary proteins. This specialized action is noted for its strong affinity to the ribosomal target.

SIVEXTRO is supplied in two distinct pharmaceutical preparations for systemic administration: a tablet intended for oral administration, and a sterile lyophilized powder provided for reconstitution before intravenous infusion. The availability of both tablet and infusion forms provides flexible options for systemic delivery.

What side effects are possible with Sivextro?

Possible side effects and safety information

The safety profile of SIVEXTRO (Tedizolid Phosphate) is categorized by government regulatory agencies based on official clinical trial data and post-marketing experience. This classification moves from the most commonly reported effects to rare, serious adverse reactions.

Adverse Reaction Classification

Side effects are grouped by frequency and the System-Organ-Class (SOC) affected. The most frequently reported adverse reactions are classified as Common, meaning they may affect up to 1 in 10 people. These commonly reported effects primarily involve the Gastrointestinal Disorders (e.g., Nausea, Diarrhea, Vomiting) and the Nervous System Disorders (e.g., Headache, Dizziness) according to official labeling.

Classification	Examples of Effects
Common	Nausea, Headache, Diarrhea, Vomiting
Uncommon	Insomnia, Somnolence, Blurred Vision

Serious Adverse Reactions and Safety Considerations

Official regulatory documents highlight the potential for certain serious adverse reactions. The risk of Clostridioides difficile-Associated Diarrhea (CDAD) is noted, which can occur even more than two months after stopping treatment. As a class effect of Oxazolidinones, there is a serious, documented risk of Serotonin Syndrome when SIVEXTRO is co-administered with other serotonergic agents, and a potential for Myelosuppression (decreased blood cell counts)

with prolonged use.

Duration-Related Patterns: The risk of Neuropathies (peripheral and optic) and severe Myelosuppression is primarily associated with treatment durations exceeding the recommended length.

Population-Specific Notes: The label includes specific safety data for Pediatric Patients (12 to <18 years), where effects like Phlebitis and increased hepatic transaminases were more common. Furthermore, the label notes that a risk to the fetus or infant cannot be excluded regarding use during Pregnancy or Lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the presentation of SIVEXTRO overdose, based on studies using high single doses (up to 1200 mg), as an exacerbation of documented adverse reactions. These manifestations often involve the gastrointestinal system, with potential for increased frequency of symptoms such as nausea, vomiting, and diarrhea.

If an overdose is suspected or confirmed, regulatory guidance is explicit: seek immediate medical attention. Patients must contact emergency medical services or a Poison Control Center right away. This immediate action is mandated to ensure prompt supportive treatment and monitoring.

Management of an overdose relies entirely on symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known or available for Tedizolid Phosphate. Furthermore, technical data indicates that hemodialysis does not result in the meaningful removal of the drug from the bloodstream, confirming supportive care as the standard procedure. Due to the drug's classification, observation for signs of serotonin syndrome is also required, as per regulatory warnings.

Therapeutic Uses of Sivextro

What SIVEXTRO Treats: Main Uses and Benefits

SIVEXTRO is commonly used for managing Acute Bacterial Skin and Skin Structure Infections (ABSSSI), which includes conditions marked by increased physiological stress caused by susceptible bacteria. This therapeutic application is relevant for conditions such as cellulitis, major abscesses, and deep wound infections. The medication is applied in managing infections associated with a range of Gram-positive bacteria, notably drug-resistant strains such as Methicillin-Resistant Staphylococcus aureus (MRSA).

Targeted Management of Drug-Resistant Skin Infections

A key therapeutic domain is the Targeted Management of Drug-Resistant Skin Infections. The medication is commonly used when the symptomatic condition is driven by pathogens that exhibit drug resistance. This capability provides support that helps ease the overall symptom burden, assisting with managing conditions where a resistant pathogen is highly suspected or confirmed.

Resolution of Systemic and Local Symptom Clusters

The medication plays a role in managing the localized acute inflammation (e.g., extensive redness, swelling, and induration) and the corresponding systemic infectious responses such as fever. This action offers supportive relief that helps patients cope more steadily with symptom fluctuations.

Quick Facts: Therapeutic Focus

Therapeutic Domain	Focus of Relief	Context of Use
Symptom Clusters	Redness, swelling, and hardening (induration)	Applied in clinical settings that involve acute or unstable symptom patterns
Target Pathogen	Drug-resistant Gram-positive bacteria (MRSA)	Used when symptoms escalate temporarily and supportive relief is needed

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Official Eligibility Profile for SIVEXTRO

The eligibility for SIVEXTRO (Tedizolid Phosphate) is defined by official regulatory bodies based on specific contraindications, age thresholds, and pre-existing health conditions. Use is established for adult and adolescent patients 12 years of age and older.

Who Must Not Use SIVEXTRO (Contraindications)

Classification	Restriction
Absolute Exclusion	Patients with known hypersensitivity to Tedizolid Phosphate or to any of the product’s inactive ingredients.

Age- and Condition-Based Eligibility

Population	Official Eligibility Status
Children	Safety and effectiveness are not established in children below 12 years of age in some regulatory documents.
Organ Function	No dosage adjustment is necessary for patients with any degree of renal impairment or with mild to moderate hepatic impairment. Use is not recommended in severe hepatic impairment as the safety profile has not been specifically studied.
Neutropenia	Not recommended for patients with a low neutrophil count (neutropenia), as safety and efficacy have not been adequately evaluated in this specific population.
Pregnancy/Lactation	Avoided during pregnancy due to potential fetal risk shown in animal studies. Use is not recommended during breastfeeding as a risk to the infant cannot be excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sivextro (tedizolid phosphate) has documented interactions based on its potential to affect certain transport systems and enzymes in the body.

Interacting Medicines and Classes

The following categories and specific agents are associated with official interaction statements:

Category	Context	Interaction Type
Serotonergic Agents (e.g., specific antidepressants, opioids)	Caution required	Theoretical risk of serotonin syndrome due to Sivextro's reversible, nonselective monoamine oxidase (MAO) inhibition
BCRP Substrates (taken orally)	Monitoring required	Sivextro (oral formulation) may increase the plasma concentration of orally administered Breast Cancer Resistance Protein (BCRP) substrates

Regulatory Constraints

Because Sivextro is a reversible, nonselective MAO inhibitor in vitro, caution is warranted when co-administering it with serotonergic agents. This is based on the theoretical risk of serotonin syndrome, which has been reported within the oxazolidinone class of medicines. The co-administration of oral Sivextro with oral BCRP substrates requires monitoring for potential adverse reactions related to increased exposure to the co-administered medicine.

The official interaction profile highlights two key mechanisms: the potential for MAO inhibition (which affects serotonergic agents) and the inhibition of the BCRP efflux transporter (which affects other medicines taken orally). These interactions define the requirements for caution and monitoring during concomitant use.

Mechanism of Action

Molecular Targeting of the Bacterial Protein Synthesis Factory

Tedizolid, the active moiety of Sivextro, functions as a highly specific inhibitor by precisely binding to the 23S ribosomal RNA within the bacteria's 50S ribosomal subunit. This targeted molecular interaction engages the machinery responsible for building proteins, the most fundamental pathway required for bacterial function and survival.

Blocking the 70S Ribosomal Initiation Complex

The binding to the 50S subunit locks the translational process, primarily by preventing the formation of the 70S ribosomal initiation complex . This mechanistic cascade halts the commencement of protein synthesis entirely, leading to a profound bacteriostatic effect that leads to a cessation of bacterial growth and multiplication.

Mechanistic Profile Against Resistance Pathways

The drug's structure provides strong affinity for the target site and confers a distinct mechanistic profile against resistance. This binding profile allows the molecule to inhibit the target despite the presence of the cfr gene (which causes ribosomal modification). This capability provides for the functional inhibition of the ribosome even in the presence of cfr-mediated ribosomal modification.

Dosage and Administration Information

How to Use Sivextro: Administration Guidelines

Sivextro (tedizolid phosphate) is intended for systemic use and is administered via highly defined protocols. The primary usage structure is based on a fixed dose for a short duration, allowing for flexibility in the route of administration.

Administration Scope

Entity	Instruction
Route of Administration	Approved as an oral tablet or as an intravenous (IV) infusion.
Dosing Schedule	The standard regimen is 200 mg once daily for a fixed duration of 6 days.
Timing in Relation to Meals	Oral tablets may be taken with or without food.
Special Procedural Conditions	The IV formulation must be administered as an infusion over 60 minutes; it is not intended to be given as a rapid bolus.

Population and Dose Management Rules

The usage protocol is standardized for many adult groups. No dosage adjustment is required for older adults (ge 65 years) or in patients with renal or hepatic impairment. A different, weight-based IV dosing regimen is required for pediatric patients weighing less than 35 kg.

The standard protocol allows for sequential therapy, where treatment may begin with the IV infusion and then switch to the oral tablet to complete the 6-day course.

Missed Dose Rules

If a dose is missed, it should be administered as soon as possible, unless the time remaining before the next scheduled dose is less than 8 hours. If less than 8 hours remain, the missed dose must be skipped. Patients must not take a double dose to compensate for the omission.

Connection to the Overall Use Protocol

The instructions establish a fixed-dose, fixed-duration protocol across two flexible administration routes, which simplifies the procedural use of the medication. The explicit rules for sequential IV-to-oral therapy and the lack of dose adjustments for key populations define a standardized, clear administrative framework that is consistently applied.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Research explored a potential mechanism involving the inhibition of bacterial protein synthesis through binding to the 50S ribosomal subunit. Clinical studies for Sivextro (tedizolid phosphate) have focused on patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including cellulitis, major cutaneous abscesses, and wound infections, primarily caused by susceptible Gram-positive bacteria, such as MRSA (methicillin-resistant Staphylococcus aureus).

Efficacy Studies

Two pivotal Phase 3 trials (ESTABLISH-1 and ESTABLISH-2) compared a 6-day course of Sivextro to a 10-day course of a similar antibiotic (linezolid) in adult patients. These studies were designed to assess whether Sivextro was non-inferior to the comparator.

Early Clinical Response

The primary endpoint in these trials was the early clinical response, defined as a reduction of at least 20% in the size of the infected lesion area 48 to 72 hours after starting treatment.

In both studies, the results demonstrated that Sivextro was statistically non-inferior to the comparator in achieving this early clinical response.

Pharmacokinetic Profile

Research has evaluated how the compound is absorbed and eliminated by the body. Sivextro has high oral bioavailability (over 90%), allowing for seamless switching between intravenous and oral administration. The compound is primarily metabolized in the liver, and it has a longer half-life compared to the related antibiotic, supporting once-daily dosing.

Frequently Asked Questions (FAQ)

Common questions about Sivextro (FAQ)

Q: Is Sivextro the same as Zyvox (Linezolid)?

Sivextro (tedizolid) is a newer, second-generation antibiotic that belongs to the same oxazolidinone class as Linezolid (Zyvox), but they are different medications. Regulatory documents indicate Sivextro was compared directly to Linezolid in clinical trials.

Q: Can older people use Sivextro without special dose changes?

According to official product information, no dosage adjustment is necessary for older adults (65 years of age and older). The standardized administration protocol applies to this population.

Q: Can children take Sivextro?

Official information states that use is established for adolescent and adult patients 12 years of age and older. Safety and effectiveness are generally not established in children below 12 years of age.

Q: Can Sivextro interact with antidepressant medications?

Caution is warranted when Sivextro is used alongside certain serotonergic agents, which includes some types of antidepressants. This is based on the theoretical risk of a condition called serotonin syndrome, due to Sivextro’s reversible MAO inhibition. This requires caution when considering co-administration, as noted in regulatory documents.

Q: Are there any dietary restrictions when taking Sivextro?

No specific dietary restrictions (e.g., related to tyramine) are listed in the official prescribing information for Sivextro. The oral tablets may be taken with or without food.

Q: How quickly does Sivextro typically start to work?

The drug’s initial impact is monitored using the early clinical response endpoint in clinical trials. This response is typically assessed between 48 and 72 hours after beginning treatment.

Q: Can Sivextro cause problems with sleep?

Official labeling lists both Insomnia (difficulty falling or staying asleep) and Somnolence (sleepiness) as uncommon side effects that may occur.

Q: Is it safe to drive while taking Sivextro?

Official labeling notes that the drug may affect alertness or coordination. Activities requiring concentration, such as driving, should be approached with caution until the user is aware of how the medication affects their coordination.

Q: Can Sivextro be used for tooth infections?

The official indication, as approved by regulatory bodies, is limited to the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by designated susceptible bacteria.

Q: What is the risk of having an allergic reaction to Sivextro?

Hypersensitivity (allergic reaction) to the drug or its ingredients is an official contraindication, meaning the drug should not be used. Regulatory data indicates that serious adverse reactions occurred in approximately 1.8% of patients in clinical trials.

Q: Is Sivextro considered a 'strong' or 'last resort' antibiotic?

The drug is designated for use against specific infections, including those caused by certain bacteria that may be resistant to standard antibiotics, such as MRSA (methicillin-resistant Staphylococcus aureus). This defines its role in certain treatment scenarios.

Q: Can Sivextro cause nerve issues or tingling in hands/feet?

Peripheral neuropathy (nerve issues or tingling) is a risk associated with treatment durations exceeding the recommended length in this antibiotic class. However, this effect has not been reported in patients treated for the recommended 6-day duration of Sivextro.

Q: How long does Sivextro stay in your system after you stop taking it?

Regulatory information indicates the drug has a relatively long half-life when compared to the related antibiotic. This half-life is the characteristic that supports its once-daily dosing schedule.

Q: Is it possible to become resistant to Sivextro?

Prescribing the drug without a proven or strongly suspected bacterial infection increases the risk of the development of drug-resistant bacteria. Its use is intended for confirmed or strongly suspected susceptible bacterial infections.

Q: Can Sivextro cause diarrhea, and if so, how serious is it?

Diarrhea is listed as a common side effect. A potentially more serious adverse reaction called Clostridioides difficile-Associated Diarrhea (CDAD) is a documented risk and can occur even after treatment has stopped. This serious condition requires immediate attention.

Q: Is it common to feel dizzy or lightheaded while on Sivextro?

Dizziness is listed as one of the most common adverse reactions in official regulatory documents. Clinical trial data indicates this effect occurred in approximately 2% of patients.

Q: Is Sivextro used in hospital settings often?

The drug is available as both an oral tablet, which is suitable for outpatient use, and an intravenous (IV) infusion form. The IV form is typically used for initial treatment in clinical or hospital settings.

Q: Are there any known long-term side effects from Sivextro use?

The risks of severe effects such as neuropathies (nerve damage) and myelosuppression (decreased blood cell counts) are primarily associated with treatment durations exceeding the recommended 6-day course. The short treatment length limits the likelihood of these long-term class effects.

How should Sivextro be stored and disposed of?

How to Store and Dispose of SIVEXTRO (Tedizolid Phosphate)

Storage Requirements

SIVEXTRO tablets must be kept at Controlled Room Temperature, typically 20 C to 25 C, and stored away from excess moisture, heat, and light. The tablets should remain in their original container, with the cap tightly closed, and stored in blister packs until use. The medicine must always be stored out of the sight and reach of children.

Stability and Handling (Intravenous Solution)

Once the SIVEXTRO powder for injection is prepared, the total time for reconstitution, dilution, and storage must not exceed 24 hours. This time limit applies whether the solution is stored at room temperature or refrigerated. The vials are for single use only and require aseptic technique for preparation. Vigorous shaking of the vial must be avoided.

Official Disposal Rules

Any unused portion of the prepared intravenous solution must be discarded. Disposal of expired tablets or other unused medicine must be completed in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.